The European Asthma Research & Innovation Partnership (EARIP) was a project led and co-ordinated by Asthma UK and funded by a European Commission FP7 grant. It aimed to identify areas of unmet need and poor outcomes that need focus and investment to transform health outcomes in Europe; reducing asthma attacks, hospitalisations and even deaths.
The Partnership has identified 15 key areas, which provide a blueprint for investment in asthma research, development and innovation. We have got, for the first time, international, cross-disciplinary consensus on the priorities in asthma research that need addressing.
This ‘roadmap’ was produced after detailed and rigorous analysis using internationally recognised methodology. The process was led by a group of leading experts from across academia, patient organisations, health professionals and pharmaceutical companies.
The work done through EARIP highlights the critical gaps in our basic understanding of asthma and shows how we can drive innovation and competitiveness to prevent, manage and eventually cure asthma. Priorities for investment include new treatments, new and better diagnostic tests and a new approach to self-management through disruptive but transformational e- and m-health technologies. This would not only improve health outcomes for people with asthma, but would create jobs, attract further investment and allow the UK to lead the world in preventing, managing and curing asthma for the global community of over 300 million people with asthma.
Asthma UK is working with national and international funders to ensure that these areas of research receive greater investment, and help to drive future innovation. Asthma UK is keen to facilitate new collaborations and use our networks to connect people. If you have ideas about how the UK and its partners can drive a revolution in asthma research and innovation to transform asthma outcomes for this generation and the next, please contact email@example.com.
The European Asthma Research & Innovation Partnership was supported by the European Commission through the FP7 programme (GA: 602077)